 we report on our first quarter 2021 financial results and provide an outlook for the remainder of the year. 
 our net earnings were $117 million compared to a loss of $2 million in the first quarter of 2020. in terms of earnings per share, this works out to a basic earnings of $0.43 per share and diluted earnings of $0.37 per share. Revenue in the quarter was nearly $203 million, 44 times what it was in the first quarter of 2020. as a result of the success of bamlanivimab, we now have 16 programs under contract across three partners effectively. 
 we expect to continue to see a robust number of program starts in 2021, with the increase in program starts as the leading indicator of this. in terms of revenue, we achieved royalty revenues of $171 million and a milestone payment of $7 million in the first quarter of 2021. 
 these are all attributable to the sales of bamlanivimab alone and in combination with other antibodies including etesevimab. 
 1404 is currently being evaluated both alone and in a three-way combination together with bamlanivimab and etesevimab. 1404 has combined breadth and potency that we believe